尼古丁替代疗法的全球市场:现状分析与预测(2021年～2027年)

全球尼古丁替代疗法的市场规模在预测期间(2021年～2027年)中预计将以约14％的年复合成长率成长。

政府启发计划的增加、呼吸系统疾病等慢性病增加，以及越来越多的年轻人沉迷于吸烟和烟草消费，这些都预计将推动尼古丁替代疗法市场的增长。

本报告提供全球尼古丁替代疗法市场的相关调查，提供市场洞察，市场趋势，竞争模式，企业概要等全面性资讯。

目录

第1章 市场简介

• 市场定义
• 限制
• 相关利益者
• 报告所使用的货币

第2章 调查方法或假设

• 尼古丁替代疗法市场调查流程
• 尼古丁替代疗法市场调查手法
• 预测方法
• 受访者简介
• 尼古丁替代疗法市场调查的主要目的

第3章 市场摘要

第4章 摘要整理

第5章 尼古丁替代疗法市场上COVID-19影响

第6章 尼古丁替代疗法市场收益(2019年～2027年)

第7章 市场洞察:各类型

• 口香糖
• 贴片
• 锭剂
• 吸入器
• 其他

第8章 市场洞察:各流通管道

• 医院药局
• 零售药局
• 线上药局

第9章 市场洞察:各地区

• 北美的尼古丁替代疗法市场
  • 美国
  • 加拿大
  • 其他的北美
• 欧洲的尼古丁替代疗法市场
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 其他的欧洲
• 亚太地区的尼古丁替代疗法市场
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 其他的亚太地区
• 其他

第10章 尼古丁替代疗法市场动态

• 推动市场要素
• 市场课题
• 影响分析

第11章 尼古丁替代疗法市场机会

第12章 尼古丁替代疗法市场趋势

第13章 相关法规

第14章 需求与供给面分析

• 需求面分析
• 供给面分析

第15章 价值链分析

第16章 竞争模式

• 竞争情形
  • 波特的五力分析

第17章 公司概要

• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis AG
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• AstraZeneca
• Johnson & Johnson Private Limited
• Merck & Co., Inc.
• Cipla Inc.

第18章 免责声明

The nicotine replacement therapy is expected to witness a CAGR of around 14% during the forecast period (2021-2027). Nicotine replacement therapy (NRT) is effective in helping people quit smoking through patches, inhalers, gums, sprays, and lozenges that are free of the toxic compounds found in tobacco. Factors that are accelerating its market growth such as growing awareness programs by the government, rising chronic diseases such as respiratory diseases, and cardiovascular diseases coupled with the increasing young population addicting to smoking or tobacco consumption are accentuating the market size of nicotine replacement therapy. In addition, technological advancements in the NRT market are continuing, resulting in an increase in the number of people moving to advanced products. The acceptance of NRT is anticipated to be aided by new innovations such as heat-not-burn products, flavored chewing gums, and lozenges are propelling the market growth.

Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, AstraZeneca, Johnson & Johnson Private Limited, Merck & Co. Inc., and Cipla Inc. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with new and advanced nicotine replacement therapy.

Insights Presented in the Report

"Amongst type, gums category accounted for the majority share in the market in 2020"

Based on type, the nicotine replacement therapy market is segmented into gums, patches, lozenges, inhalers, and others. In 2020, The gums category is anticipated to witness a significant growth rate over the forecast period owing to the rising prevalence of chronic diseases, increasing awareness of smoking & tobacco consumption, and the introduction of technologically advanced products are the factors driving the demand for nicotine replacement therapy. Therefore, increasing awareness worldwide is anticipated to increase the NRT product's sales during the forecast period. Furthermore, The World Health Organization (WHO) Framework Convention on Tobacco Control (WHO FCTC) is the first international public health treaty negotiated under WHO auspices. This treaty contains guidelines and requirements for the implementation of the most cost-effective tobacco control measures available necessary for reducing the smoking epidemic.

"Amongst distribution channel, offline category is expected to witness highest CAGR during the forecast period"

Based on distribution channel, the nicotine replacement therapy market is categorized into online pharmacies and offline pharmacies. In 2020, the offline category dominated the market. This is mainly due to the increased number of patients who are suffering from chronic diseases such as cancer, respiratory disease, and excessive smoking habits. For instance, according to the Centers for Disease Control and Prevention (CDC), People who smoke cigarettes are 15 to 30 times more likely to get lung cancer or die from lung cancer than people who do not smoke. These factors will increase sales of NRT products & spread awareness about the importance of prohibiting smoking. In addition, online pharmacies are projected to witness the fastest growth during the forecast period. Furthermore, the flexibility, comfort, and convenience provided by the online purchase of medications are major factors driving the segment.

"North America to witness significant growth during the forecast period"

For a better understanding of the market, the report provides a detailed analysis of major regions and countries including North America (U.S., Canada, Rest of America); Europe (Germany, U.K., France, Spain, Italy, Rest of Europe); Asia-Pacific (China, India, Japan, Australia, Rest of Asia-Pacific) and Rest of World. In 2020, North America accounted for a significant market share. This is mainly due to the rising adoption rate of NRT products, heated tobacco, and well-established healthcare infrastructure are some key factors that will drive the market growth rate in this region. Furthermore, to reduce smoking & tobacco consumption the U.S. Food and Drug Administration (FDA) approved nicotine replacement therapy by introducing products such as nicotine gums, patches, lozenges, and others. pharmaceutical companies GlaxoSmithKline and Johnson & Johnson have been supplying products worldwide.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

• The report presents a quick review of overall industry performance at one glance.

• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

• The study comprehensively covers the market across different segments.

• Deep dive regional level analysis of the industry.

Customization Options:

The nicotine replacement therapy market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Limitation
• 1.3. Stake Holders
• 1.4. Currency used in Report

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Nicotine Replacement Therapy Market
• 2.2. Research Methodology of the Nicotine Replacement Therapy Market
• 2.3. Forecasting Method
• 2.4. Respondent Profile
• 2.5. Main Objective of the Nicotine Replacement Therapy Market Study

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 NICOTINE REPLACEMENT THERAPY MARKET COVID-19 IMPACT

6 NICOTINE REPLACEMENT THERAPY MARKET REVENUE, 2019-2027F

7 MARKET INSIGHTS BY TYPE

• 7.1. Gums
• 7.2. Patches
• 7.3. Lozenges
• 7.4. Inhalers
• 7.5. Others

8 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 8.1. Hospitals Pharmacy
• 8.2. Retail Pharmacy
• 8.3. Online Pharmacy

9 MARKET INSIGHTS BY REGION

• 9.1. North America Nicotine Replacement Therapy Market
  • 9.1.1. U.S.
  • 9.1.2. Canada
  • 9.1.3. Rest of America
• 9.2. Europe Nicotine Replacement Therapy Market
  • 9.2.1. Germany
  • 9.2.2. U.K.
  • 9.2.3. France
  • 9.2.4. Spain
  • 9.2.5. Italy
  • 9.2.6. Rest of Europe
• 9.3. Asia-Pacific Nicotine Replacement Therapy Market
  • 9.3.1. China
  • 9.3.2. India
  • 9.3.3. Japan
  • 9.3.4. Australia
  • 9.3.5. Rest of Asia-Pacific
• 9.4. Rest of the world Nicotine Replacement Therapy Market

10 NICOTINE REPLACEMENT THERAPY MARKET DYNAMICS

• 10.1. Market Drivers
• 10.2. Market Challenges
• 10.3. Impact Analysis

11 NICOTINE REPLACEMENT THERAPY MARKET OPPORTUNITIES

12 NICOTINE REPLACEMENT THERAPY MARKET TRENDS

13 LEGAL & REGULATORY FRAMEWORK

14 DEMAND AND SUPPLY SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

• 16.1. Competitive Landscape
  • 16.1.1. Porter's Five Forces Analysis

17 COMPANY PROFILED

• 17.1. Pfizer Inc.
• 17.2. GlaxoSmithKline plc
• 17.3. Novartis AG
• 17.4. Mylan N.V.
• 17.5. Teva Pharmaceutical Industries Ltd.
• 17.6. Sanofi
• 17.7. AstraZeneca
• 17.8. Johnson & Johnson Private Limited
• 17.9. Merck & Co., Inc.
• 17.10. Cipla Inc.

18 DISCLAIMER